It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.
The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...
Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...
The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...
The Biden administration is proposing that Medicare and Medicaid pay for popular anti-obesity drugs for more Americans.
The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...
The Biden administration proposed a rule to let Medicare and Medicaid cover obesity drugs like Ozempic. Millions would ...
1d
Investors are assessing the likelihood Trump will deliver on his threat to impose fresh tariffs on China, Canada and Mexico.
Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.
U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback